Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction

Journal of Clinical Psychopharmacology

Volumn 22, Issue 4, 2002, Pages 419-423

  Spina, Edoardo ^a,b   Avenoso, Angela ^a   Scordo, Maria Gabriella ^a   Ancione, Maria ^b   Madia, Aldo ^b   Gatti, Giuliana ^c   Perucca, Emilio ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Centers of Mental Health   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE; PALIPERIDONE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DEPRESSION; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; HUMAN; MALE; NAUSEA; PARKINSONISM; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; STATISTICS, NONPARAMETRIC;

EID: 0036328632     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200208000-00014     Document Type: Article

References (33)

1. Clinical review of risperidone
2. Absorption, metabolism and excretion of risperidone in humans
3. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
4. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4
5. Different enantios-elective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes
6. Survey on pharmacodynamics of the new antipsychotic risperidone
7. Serum concentrations and side effects in psychiatric patients during risperidone therapy
8. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia
9. Fluoxetine
10. Elevation of plasma concentrations of haloperidol after addition of fluoxetine
11. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia
12. Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications
13. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate
14. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia
15. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A
16. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection
17. Issues in methodology and applications for therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers in treated patients
18. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification
19. Drug-induced extrapyramidal disorders
20. The positive and negative syndrome scale (PANSS) for schizophrenia
21. A rating scale for depression
22. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors
23. Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes
24. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine
25. No effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia
26. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver
27. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6, the source of the sparteine/debrisoquine oxidation polymorphism
28. Inhibition of desipramine hydroxylation by serotonin reuptake inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo
29. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation
30. The effects of serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4-hydroxylase activity in human liver microsomes
31. Inhibition of alprazolam metabolism in vitro: Effects of the serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine
32. Extrapyramidal symptoms in patients treated with risperidone
33. Extrapyramidal symptoms associated with the selective serotonin reuptake inhibitors